Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.

[1]  J. Chan,et al.  Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension. , 2019, Journal of hepatology.

[2]  R. Loomba,et al.  The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH , 2019, Hepatology.

[3]  Z. Goodman,et al.  The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials , 2019, Hepatology.

[4]  B. Neuschwander‐Tetri,et al.  Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum , 2019, Hepatology.

[5]  F. Tacke,et al.  Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD , 2019, Hepatology.

[6]  A. Spada,et al.  Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte‐Mediated Paracrine Mechanism , 2019, Hepatology communications.

[7]  J. Chan,et al.  Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End‐Stage Liver Disease Scores Compared With Placebo , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  Andrew A. Li,et al.  Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft , 2018, Journal of clinical and translational hepatology.

[9]  Y. Koyama,et al.  Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation , 2018, Journal of Molecular Medicine.

[10]  Gianluca Svegliati-Baroni,et al.  Lipotoxicity and the gut-liver axis in NASH pathogenesis. , 2018, Journal of hepatology.

[11]  R. Franchis.  Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension , 2015 .

[12]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[13]  Seamus J. Martin,et al.  Proteolytic Processing of Interleukin-1 Family Cytokines: Variations on a Common Theme. , 2015, Immunity.

[14]  G. Gores,et al.  The pan‐caspase inhibitor Emricasan (IDN‐6556) decreases liver injury and fibrosis in a murine model of non‐alcoholic steatohepatitis , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[15]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. , 2015, Gastroenterology.

[16]  G. D’Amico,et al.  Competing risks and prognostic stages of cirrhosis: a 25‐year inception cohort study of 494 patients , 2014, Alimentary pharmacology & therapeutics.

[17]  E. Ulukaya,et al.  Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. , 2009, Medical science monitor : international medical journal of experimental and clinical research.

[18]  G. Gores,et al.  Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. , 2003, Gastroenterology.

[19]  G. D’Amico,et al.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.